Document is current
Any future updates will be listed below
-
Authors
Emmerich, Kevin https://orcid.org/0000-0002-0088-1333
White, David T.
Kambhampati, Siva P.
Casado, Grace L.
Fu, Tian-Ming
Chunawala, Zeeshaan
Sahoo, Arpan https://orcid.org/0000-0002-6375-3048
Nimmagadda, Saumya
Krishnan, Nimisha
Saxena, Meera T.
Walker, Steven L.
Betzig, Eric https://orcid.org/0000-0002-4192-1274
Kannan, Rangaramanujam M. https://orcid.org/0000-0002-3712-7836
Mumm, Jeff S. https://orcid.org/0000-0002-2575-287X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (R01OD020376)
U.S. Department of Health & Human Services | NIH | National Eye Institute (F31EY032790)
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01EY025304)
U.S. Department of Health & Human Services | NIH | National Eye Institute
- License Information
-
More Information
Article History
Received: 22 February 2021
Accepted: 2 May 2023
First Online: 18 May 2023
Competing interests
: J.S.M. holds patents for the NTR inducible cell ablation system (US #7,514,595) and uses thereof (US #8,071,838 and US#8431768). R.M.K. and S.P.K. have been awarded pending patents relating to the hydroxyl dendrimer platform for ocular therapies. RMK and his wife (Sujatha Kannan) are co-founders/board members and have financial interests in Ashvattha Therapeutics Inc., a start-up focusing on clinical translation of the dendrimer platform. The remaining authors declare no competing interests.
